Intellia Therapeutics Inc

Intellia Therapeutics Inc

NTLA

Market Cap$2.52B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Intellia Therapeutics IncIntellia Therapeutics Inc-5.20%---
$58.00

Target Price by Analysts

131.3% upsideIntellia Therapeutics Target Price DetailsTarget Price
$-4.94

Current Fair Value

119.7% downside

Overvalued by 119.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.52 Billion
Enterprise Value-
Dividend Yield$0.0 (0.0%)
Earnings per Share$-5.35
Beta2.04
Outstanding Shares96,475,421
Avg 30 Day Volume1,950,667

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-5.18
PEG-124.05
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income0
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Intellia Therapeutics Inc

211 employees
CEO: John Leonard

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...